EFPIA Patients W.A.I.T. Indicator 2020 Survey

A new report released by the European Federation of Pharmaceutical Industries and Associations examines how quickly countries across Europe provided access to 152 new drugs that came to market between 2016 and 2019.

This iteration of the Patients W.A.I.T. (Waiting to Access Innovative Therapies) Indicator marks the 14th annual version of the largest European study into innovative medicines availability and the time to patient-access. The charts in the report cover an broader set of countries than in previous years, providing a full European picture on availability (34 countries, 24 EU and 10 non-EU). 

Germany led the group with a 88% availability rate, followed by Denmark (86%) and Austria (82%). The EU average was 49%. 

The report notes that some drug approvals over the period took as long as 1,600 to 1,800 days – close to 4½  to 5 years – while others were done in just a couple of months. The German system also led in days-to-availability, at an average of 120 days in comparison to the European average of 504 days. 

The report also provides a comprehensive break-down by oncology, orphan drugs, and combination therapies |